IF 4.5 2区 医学 Q1 ONCOLOGY
Cancers Pub Date : 2024-12-04 DOI:10.3390/cancers16234064
Haifa Kathrin Al-Ali, Andrew T Kuykendall, Catherine E Ellis, Janardhan Sampath, Ruben Mesa
{"title":"Anemia in Myelofibrosis: A Focus on Proactive Management and the Role of Momelotinib.","authors":"Haifa Kathrin Al-Ali, Andrew T Kuykendall, Catherine E Ellis, Janardhan Sampath, Ruben Mesa","doi":"10.3390/cancers16234064","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Anemia is a common and progressive clinical manifestation of myelofibrosis that may occur as part of the disease pathogenesis as well as due to the myelosuppressive effects of some treatments, with a substantial impact on quality of life, prognosis, and healthcare resource utilization. Despite these burdens, anemia management has traditionally been a secondary priority to spleen and symptom control, due in part to the limitations of available therapeutic approaches. With the initial regulatory approvals of momelotinib, a Janus kinase 1 (JAK1), JAK2, and activin A receptor type 1 inhibitor that provides anemia-related benefits in addition to addressing splenomegaly and symptoms, re-evaluation of anemia as an early and prominent treatment consideration is warranted. <b>Methods:</b> In this review, we discuss the journey of patients with myelofibrosis and anemia across various severities and clinical scenarios. <b>Results:</b> Summarized are traditional approaches to anemia management and the clinical trial efficacy and safety data that support momelotinib as an option in each setting from mild to severe anemia, including in the context of co-occurring thrombocytopenia. <b>Conclusions:</b> With the availability of momelotinib and other emerging therapies directed at anemia control, early treatment of anemia to avoid progression and support improvement in eligible patients with myelofibrosis should be a primary consideration.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"16 23","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/cancers16234064","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:贫血是骨髓纤维化常见的渐进性临床表现,可能是疾病发病机制的一部分,也可能是某些治疗方法的骨髓抑制作用所致,对生活质量、预后和医疗资源利用率有很大影响。尽管存在这些负担,但贫血治疗在传统上一直是脾脏和症状控制的次要优先事项,部分原因是现有治疗方法的局限性。莫美洛替尼是一种 Janus 激酶 1 (JAK1)、JAK2 和活化素 A 受体 1 型抑制剂,除了能治疗脾肿大和症状外,还能提供贫血相关的益处。方法:在这篇综述中,我们讨论了骨髓纤维化和贫血患者在不同严重程度和临床情况下的治疗历程。结果:总结了治疗贫血的传统方法以及临床试验的疗效和安全性数据,这些数据支持莫美洛替尼作为从轻度到重度贫血的各种情况下的一种选择,包括并发血小板减少症的情况。结论随着莫美洛替尼和其他针对贫血控制的新兴疗法的出现,应将早期治疗贫血作为首要考虑因素,以避免病情恶化并支持符合条件的骨髓纤维化患者病情改善。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Anemia in Myelofibrosis: A Focus on Proactive Management and the Role of Momelotinib.

Background: Anemia is a common and progressive clinical manifestation of myelofibrosis that may occur as part of the disease pathogenesis as well as due to the myelosuppressive effects of some treatments, with a substantial impact on quality of life, prognosis, and healthcare resource utilization. Despite these burdens, anemia management has traditionally been a secondary priority to spleen and symptom control, due in part to the limitations of available therapeutic approaches. With the initial regulatory approvals of momelotinib, a Janus kinase 1 (JAK1), JAK2, and activin A receptor type 1 inhibitor that provides anemia-related benefits in addition to addressing splenomegaly and symptoms, re-evaluation of anemia as an early and prominent treatment consideration is warranted. Methods: In this review, we discuss the journey of patients with myelofibrosis and anemia across various severities and clinical scenarios. Results: Summarized are traditional approaches to anemia management and the clinical trial efficacy and safety data that support momelotinib as an option in each setting from mild to severe anemia, including in the context of co-occurring thrombocytopenia. Conclusions: With the availability of momelotinib and other emerging therapies directed at anemia control, early treatment of anemia to avoid progression and support improvement in eligible patients with myelofibrosis should be a primary consideration.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cancers
Cancers Medicine-Oncology
CiteScore
8.00
自引率
9.60%
发文量
5371
审稿时长
18.07 days
期刊介绍: Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信